{
    "Trade/Device Name(s)": [
        "Elecsys\u00ae Testosterone II Immunoassay",
        "Testosterone II Assay",
        "Elecsys Testosterone II Assay"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K093421",
    "Predicate Device Reference 510(k) Number(s)": [
        "K964889"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ"
    ],
    "Summary Letter Date": "April 19, 2010",
    "Summary Letter Received Date": "April 20, 2010",
    "Submission Date": "October 23, 2009",
    "Regulation Number(s)": [
        "21CFR862.1680"
    ],
    "Regulation Name(s)": [
        "Testosterone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Elecsys 2010",
        "MODULAR ANALYTICS E170",
        "cobas e 411",
        "cobas e 601"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Competitive immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys Testosterone II Immunoassay, a competitive ECLIA for quantitative determination of testosterone in human serum and plasma.",
    "Indications for Use Summary": "Immunoassay for the in vitro quantitative determination of testosterone in human serum and plasma to aid in diagnosis and treatment of androgen-related disorders including hypogonadism, puberty disorders, impotence in males, and hirsutism/virilization in females.",
    "fda_folder": "Clinical Chemistry"
}